Glioblastoma | Norton Healthcare

Indication: Glioblastoma

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Sub-indication: CNS Cancer

Study Type: Device Study

Principal Investigator: Renato LaRocca, M.D.
Norton Brain Tumor Center

Sponsor: Sponsor: NovoCure

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.